• Citer

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.

par Raoul, Jean-Luc;Van Laethem, Jean-Luc ;Peeters, Marc;Brezault, Catherine;Husseini, Fares;Cals, Laurent;Nippgen, Johannes;Loos, Anja-Helena;Rougier, Philippe
Référence BMC cancer, 9, page (112)
Publication Publié, 2009

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer.